SinoRDA

SinoRDA is a clinical-stage biopharmaceutical company headquartered in Guiyang, China, specializing in the development and commercialization of innovative therapies for gastrointestinal diseases, oncology, and autoimmune disorders. The company's lead product, Linaprazan Glurate (X842), is a next-generation potassium-competitive acid blocker (P-CAB) that received approval from China's NMPA in late 2024 for the treatment of reflux esophagitis. SinoRDA's diverse pipeline also includes advanced cell therapies such as the sentinel lymph node T-cell vaccine (SND002), oncolytic viruses (SND005), and novel bispecific antibodies (SND006) targeting inflammatory bowel disease. Through strategic partnerships with global and domestic firms like Cinclus Pharma, WuXi Biologics, and Shanghai Pharmaceuticals, SinoRDA is advancing its mission to address significant unmet medical needs. The company leverages proprietary platforms like Neo-Pred for neoantigen prediction and specialized T-cell production technologies to drive its oncology and immunology programs.